Pulmonary and Total Blood Volume in COPD
Key facts
- Where
- Copenhagen, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 80 years old?
Where in Denmark
- Center for Aktiv SundhedCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Trial code
- NCT07428785
- Record updated
- 2 October 2026
- Original description
Background Patients with chronic obstructive lung disease (COPD) suffer from a progressive loss of lung function that leads to poor quality of life, and often invalidity and early death. This is markedly affected by a reduced exercise capacity and dyspnoea, but the underlying mechanisms are unknown. In the present study, we aim to investigate whether this may involve a reduced pulmonary blood volume secondarily to a reduced total blood volume.Read full original descriptionShow less
Pulmonary and Total Blood Volume in COPD: A Prosoective Matched Comparative Study
Background Patients with chronic obstructive lung disease (COPD) suffer from a progressive loss of lung function that leads to poor quality of life, and often invalidity and early death. This is markedly affected by a reduced exercise capacity and dyspnoea, but the underlying mechanisms are unknown. In the present study, we aim to investigate whether this may involve a reduced pulmonary blood volume secondarily to a reduced total blood volume.
Methods Design: Prospective matched comparative study Intervention: None
Outcomes:
The primary outcome is pulmonary blood volume estimated to total blood volume ratio between patients with COPD and healthy controls individually matched for age, sex, and height.
Statistical design:
All statistical analyses will be performed using R statistical software version 4.1.1 (R Project for Statistical Computing) within RStudio statistical software version 1.4.1717 (RStudio), and a two-tailed p<0.05 will be considered statistically significant. Inspection of normality and variance homogeneity will be done by creating qq-plots and histogram.
Regulatory considerations: This study will be submitted for approval by Regional Ethical Committee.
Perspective: This study will help uncover fundamental aspects of the pathophysiology of COPD.
Inclusion: Inclusion criteria -patients; Men and women; 45-80 years; COPD (GOLD stage I to III); Resting arterial oxygenation > 90% Inclusion criteria - controls; Men and women; 45-80 years; Normal FEV1, FVC, FEV1/FVC, and single-breath diffusion capacity; Same sex, age (± 3 years) and height (± 5 cm) as an included COPD patient; Low- to moderate activity level defined as < 1,5 hours of structured physical activity pr. week at moderate intensity and cycling < 30 minutes/5km pr. day at moderate intensity (moderate intensity = out of breath but able to speak).
Exclusion: Previous severe or current COVID-19; Symptoms of disease within 2 weeks prior to the study; Previous severe or current COVID-19; Symptoms of disease within 2 weeks prior to the study; Symptoms of ischaemic heart disease; Known heart failure; Known malignant disease; Unstable cardiac arrhythmic disease; Known chronic lung disease; Known ischaemic heart disease; Known heart failure; Known malignant disease; Unstable cardiac arrhythmic disease; Claudication; Participation in pulmonary rehabilitation within 6 months; Pregnancy; Renal or liver dysfunction; Claudication; Pregnancy; Renal or liver dysfunction.